一项关于A型肉毒杆菌毒素治疗流涎症的随机试验。
A randomized trial of botulinum toxin A for treatment of drooling.
作者信息
Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G
机构信息
Department of Neurology, Medical Faculty of the Charité, Humboldt University, Berlin, Germany.
出版信息
Neurology. 2003 Nov 11;61(9):1279-81. doi: 10.1212/wnl.61.9.1279.
The authors compared the efficacy of three different doses (18.75, 37.5, and 75 MU per parotid gland) of botulinum toxin A (BTX-A; Dysport, Ipsen Pharma, Germany) injections vs vehicle in patients with sialorrhea (n = 32) using a single-center, prospective, double-blind, placebo-controlled dose-finding study. The primary endpoint was achieved with 75 MU BTX-A without treatment-related adverse events, suggesting BTX-A is a safe and effective treatment for patients with sialorrhea.
作者采用单中心、前瞻性、双盲、安慰剂对照的剂量探索性研究，比较了三种不同剂量（每侧腮腺18.75、37.5和75 MU）的A型肉毒杆菌毒素（BTX-A；德国益普生制药公司的Dysport）注射与赋形剂对32例流涎患者的疗效。75 MU的BTX-A达到了主要终点，且无治疗相关不良事件，这表明BTX-A是治疗流涎患者的一种安全有效的方法。
Zotero 插件